Mallinckrodt Inc

Mallinckrodt — Merger or Acquisition (December 2017)

18 slides from Mallinckrodt's merger presentation, Dec 26, 2017

  1. Slide 1: Mallinckrodt Strategic Acquisition Sucampo Pharmaceuticals

    Mallinckrodt Strategic Acquisition Sucampo Pharmaceuticals December 26, 2017 Exhibit 99.3

  2. Slide 2: Forward-looking statements

    Forward-looking statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of Sucampo Pharmaceuticals, the expected timetable for completing the transaction, future financial condition and operating results, benefits and synergies

  3. Slide 3: Forward-looking statements (continued)

    Forward-looking statements (continued) Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; The reimbursement practices of a small number of public or private insurers; Pricing pressure on certain of Mallinckrodt's products due to legal changes

  4. Slide 4: Additional Information and Notice to Investors

    Additional Information and Notice to Investors The tender offer for the outstanding Sucampo shares referenced in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substi

  5. Slide 5: Transaction highlights – acquisition of Sucampo, including AMITIZA and two development assets

    Transaction highlights – acquisition of Sucampo, including AMITIZA® and two development assets Assuming expected Q1 2018 close, MNK expects accretion to 2018 adjusted diluted earnings per share of at least $0.30, and at least double that in 2019 Potential to monetize Priority Review Voucher in Pedia

  6. Slide 6: Products marketed through commercial partners; acquired assets and status

    1 Products are marketed through commercial partners, in various geographic markets. Indications approved/marketed may vary by market. Gloria is responsible for development, commercial, and regulatory activities in China for AMITIZA; 2 OIC includes patients with chronic pain related to prior cancer o

  7. Slide 7: Acquisition builds on MNK's commitment to develop therapies for rare diseases

    Acquisition builds on MNK’s commitment to develop therapies for rare diseases 1 Graft vs Host Disease 2 Deep Partial Thickness 3 Hepatorenal Syndrome 4 Amyotrophic Lateral Sclerosis 5 Full Thickness 6 Diabetic Foot Ulcers 7 Duchenne Muscular Dystrophy 8 Vascular Endothelial Growth Factor 9 Interleuk

  8. Slide 8: Amitiza is an effective and differentiated treatment for constipation with a unique mode of action

    Amitiza is an effective and differentiated treatment for constipation with a unique mode of action (MOA) Amitiza (lubiprostone) MOA1,2 Chloride channels in the intestinal tract help regulate fluid balance Amitiza works through highly selective activation of Chloride Channel-2 (CIC-2) channels in the

  9. Slide 9: Broad indication, potential pediatric label extension, and unique MOA are key drivers for AMITIZA

    Broad indication, potential for pediatric label extension, and unique MOA are key drivers for AMITIZA Key Brands in Constipation Market FDA-Approved Indications1 Mode of Action1 2016 IMS Net Sales (% Share)3 CIC OIC IBS-C Boxed Warning1 √ √ √ √ √ √ √ √ Chloride channel activator Guanylate cyclase-C

  10. Slide 10: AMITIZA net sales will be received through commercial partnership agreements

    AMITIZA net sales will be received through commercial partnership agreements Product Transfer Royalties Milestone Payments Other Contracted transfer price paid on a ‘per unit’ basis Milestone payments determined by commercial or regulatory milestones Receives R&D revenue from AMITIZA clinical develo

  11. Slide 11: VTS-270 in Phase 3 for Niemann-Pick Type C

    VTS-270 VTS-270: in Phase 3 for Niemann-Pick Type C (NPC), a hereditary, neurodegenerative disease Niemann-Pick Disease Overview Niemann-Pick disease primarily affects children/young adults Genetic mutations affect cellular metabolism and lead to accumulation of lipids in spleen, liver, lungs, bone

  12. Slide 12: NPC Progression, Prognosis, Prevalence

    NPC Progression, Prognosis, Prevalence NPC is rare, difficult-to-diagnose, often fatal condition primarily affecting children, young adults 1 National Niemann Pick Disease Foundation ; 2 Patterson M. Niemann-Pick Disease Type C. GeneReviews. July 2013; 3 Garver WS et al. Am J Med Genet A. 143A(11):

  13. Slide 13: VTS-270 has potential to be first FDA-approved, disease-modifying agent targeting NPC

    VTS-270 has potential to be first FDA-approved, disease- modifying agent targeting NPC via direct MOA Current Options for NPC1-5 Regulatory Approval6,7 Target1-5 Antiepileptics Not approved for NPC Seizures Tricyclic antidepressants Cataplexy CNS8 stimulants Anticholinergics Dystonia and Tremor Trih

  14. Slide 14: VTS-270 Phase 1/2 trial results show clinical improvements in patients with NPC

    VTS-270 Phase 1/2 trial results show promising clinical improvements in patients with NPC 14 participants treated monthly showed slower increase in total NNSS1 compared with control cohort2 Rate of disease progression slowed for ambulation, cognition, and speech (major portions of NNSS) in participa

  15. Slide 15: CPP-1X/sulindac in Phase 3 for FAP

    CPP-1X/sulindac in Phase 3 for FAP, an often inherited genetic condition involving potentially malignant polyps Familial Adenomatous Polyposis (FAP) Overview FAP caused by genetic mutation leading to uncontrolled growth of hundreds to thousands of polyps in lower digestive tract1 Most patients (~70%

  16. Slide 16: CPP-1X/sulindac aims to provide surgical alternative in FAP patients

    CPP-1X/sulindac aims to provide surgical alternative in FAP patients, reduce polyp formation Current interventions for FAP are limited to endoscopies and gastrointestinal tract surgeries1 1 Mount Sinai Zane Cohen Centre; 2 Proof of Concept 3 Meyskens FL, et al. Cancer Prev Res. 2008;1:32-38; 4 Clini

  17. Slide 17: Acquisition of Sucampo advances efforts to address high unmet patient need

    Mallinckrodt’s acquisition of Sucampo advances our efforts to address high unmet patient need Development, regulatory expertise to gain product approvals Growing launch capabilities to optimize new product values Strong market access and HEOR1 infrastructure to maximize rare disease opportunities 1

  18. Slide 18: Sucampo aligns with MNK strategic vision

    Sucampo aligns with MNK strategic vision: Innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions Development assets serve NPC and FAP patients with limited treatment options Deepens Mallinckrodt’s focus on rare disease

Mallinckrodt — Merger or Acquisition (December 2017) on 6ix